Fowler VG Jr, Boucher HW, Corey GR, et al. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylo- coccus aureus. N Engl J Med, 355:653–65. Fridkin SK, Steward CD, Edwards JR, et al. 1999. Surveillance of anti- microbial use and antimicrobial resistance in United States hospitals: Project ICARE Phase 2. Clin Infect Dis, 29:245–52. Frank KL, Reichert EJ, Piper KE, Patel R. 2007. In vitro effects of antimicrobial agents on planktonic and bioﬁlm forms of Staphylo- coccus lugdenensis clinical isolates. Antimicrob Agents Chemother, 51:888–95. Friedman L, Alder JD, Silverman JA. 2006. Genetic chanages that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother, 50:2137–45. Fritsche TR, Rennie RP, Goldstein BP, et al. 2006. Comparison of dalba- vancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using Gram-positive organisms. J Clin Microbiol, 44:2988–90. Gales AC, Jones RN, Andrade SS, et al. 2005. In vitro activity of tigecy- cline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis, 9:348–56. Gander S, Kinnaird A, Finch R. 2005. Telavancin: in vitro activity against staphylococci in a bioﬁlm model. J Antimicrob Chemother, 56:337–43. Gaudioso de Allori MC, Jure MA, Romero C, et al. 2006. Antimicrobial resistance and production of bioﬁlms in clinical isolates of coagulase- negative staphylococcus strains. Biol Pharm Bull, 29:1592–6. Hanssen AM, Kjeldsen G, Sollid JU. 2004. Local variants of staphylococcal cassette chromosome mec in sporadic methicillin-resistant staphylococ- cus aureus and methicillin-resistant coagulase-negative staphylococci: evidence of horizontal gene transfer. Antimicrob Agents Chemother, 48:285–96. Hardy D, Amsterdam D, Mandell LA, et al. 2000. Comparative in vitro activities of ciproﬂoxacin, gemiﬂoxacin,grepaﬂoxacin, moxiﬂoxacin, oﬂoxacin, sparﬂoxacin, trovaﬂoxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrob Agents Chemother, 40:802–5. Hussain Z, Stoakes L, Lannigan R, et al. 1998. Evaluation of screening and commercial methods for Detection of methicillin resistance in coagulase-negative staphylococci. J Clin Microbiol, 36:273–4. John JF, Cosamino B, Harvin A, et al. 2006. Species prevalence of coagulase-negative staphylococci at two departments of veterans affairs medical centers. 12th International Symposium on Staphylo- coccal Infections and Staphylococci, Maestricht, The Netherlands, September 4–6, 2006. Jones ME, Karlowsky JA, Draghi DC, et al. 2003. Epidemiology and anti- biotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents, 22:406–19. Karlowsky JA, Laing NM, Baudry T, et al. 2007. In vitro activity of API- 1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. In press. Keys TF, Hewitt WL. 1973. Endocarditis due to micrococci and Staphylo- coccus epidermidis. Arch Intern Med, 132:216–20. Khardori N, Wong E, Nguyen H, et al. 1991. Effect of subinhibitory con- centrations of clindamycin and trospectomycin on the adherence of Staphylococcus epidermidis in an in vitro model of vascular catheter colonization. J Infect Dis, 164:108–13. King A, Phillips I, Kaniga K. 2004. Comparative in vitro activity of tela- vancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother, 53:797–803. Kloos WE, Bannerman TL. 1994. Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev, 7:117–40. Kloos WE, George CG. 1991. Identiﬁcation of Staphylococcus species and subspecies with the MicroScan Pos ID and Rapid Pos ID panel systems. J Clin Microbiol, 29:738–44. Therapeutics and Clinical Risk Management 2007:3(6) Antibiotic resistance in coagulase-negative staphylococci Kloos WE, Jorgensen JH, Staphylococci. 1985. In: Lannette EH, Ballows A, Hausler Jr WJ, et al. eds. Manual of Clinical Microbiology, 4th ed. Washington D.C.: American Society for Microbiology. p 145–7. Kloos WE, Schleifer KH. 1975. Simpliﬁed scheme for routine identiﬁcation of human Staphylococcus species. J Clin Microbiol, 1:82–8. Koksal F, Yasar H, Samasti M. 2007. Antibiotic resistance patterns of coagulase-negative staphylococcus strains isolated from blood cultures of septicemic patients in Turkey. Microbiol Res, In press. LaPlante KL, Rybak MJ. 2004. Clinical glycopeptide-intermediate staphy- lococci tested against arbekacin, daptomycin, and tigecycline. Diagn Microbiol Infect Dis, 50:125–30. Ligozzi M, Bernini C, Grazia M, et al. 2002. Evaluation of the VITEK 2 system for identiﬁcation and amtimicrobial susceptibility test- ing of medically relevant Gram-positive cocci. J Clin Microbiol, 40:1681–6. Lin G, Credito K, Ednie L, Applebaum PC. 2005. Antistaphylococcal activ- ity of dalbavancin, an experimental glycopeptides. Antimicrob Agents Chemother, 49:770–2. Mack D, Davies AP, Harris LG, et al. 2006. Microbial interactions in Staphy- lococcus epidermidis bioﬁlms. Anal Bioanal Chem, 387:399–408. Mongkolrattanothai K, Boyle S, Murphy TV, et al. 2004. Novel non- mecA-containing staphylococcal chromosomal cassette composite island containing pbp4 and tagf genes in a commensal staphylococcal species: a possible reservoir for antibiotic resistance islands in Staphy- lococcus aureus. Antimicrob Agents Chemother, 48:1823–36. Mushtaq S, Warner M, Johnson AP, et al. 2004. Activity of dalba- vancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. J Antimicrob Chemother, 54:617–20. Noskin GA, Siddiqui F, Stosor V, et al. 1999. In vitro activities of line- zolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother, 43:2059–62. Noto MJ, Archer GL. 2006. A subset of Staphylococcus aureus strains harboring staphylococcal cassette chromosome mec (SCCmec) type IV is deﬁcient in CcrAB-mediated SCCmec excision. Antimicrob Agents Chemother, 50:2782–8. Pankuch GA, Appelbaum PC. 2006. Postantibiotic effect of ceftibiprole against 12 Gram-positive organisms. Antimicrob Agents Chemother, 50:3956–8. Paragioudaki M, Stamouli V, Kolonitsiou F, et al. 2004. Intravenous catheter infections associated with bacteraemia: a 2-year study in a university hospital. Clin Microbiol Infect, 10:431–5. Patel R. 2005. Bioﬁlms and antimicrobial resistance. Clin Orthop Relat Res, 437:41–7. Perl TM, Rhomberg PR, Bale MJ, et al. 1994. Comparison of identiﬁcation systems for Staphylococcus epidermidis and other coagulase-negative staphylococcus Species. Diagn Microbiol Infect Dis, 18:151–5. Petersen PJ, Bradford PA, Weiss WJ, et al. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother, 46:2595–601. Pinna A, Zanetti S, Sotgiu M, et al. 1999. Identiﬁcation and antibiotic suscep- tibility of coagulase negative staphylococci isolated in corneal/external infections. Br J Ophthalmol, 83:771–3. Potoski BA, Adams J, Clarke L, et al. 2006. Epidemiological proﬁle of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis, 43:165–71. Recchia FM, Busbee BG, Pearlman RB, et al. 2005. Changing trends in the microbiologic aspects of postcataract endophthalmitis. Arch Oph- thalmol, 123:321–46. Ross JE, Anderegg TR, Sader HS, et al. 2005. Trends in linezolid sus- ceptibility pattens in 2002: report from worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn Microbiol Infect Dis, 52:53–8. Rupp ME, Archer GL. 1994. Coagulase-negative staphylococci: pathogens associated with medical progress. Clin Infect Dis, 19:231–43. 1151